Oculis Holding AG announced it will present the development of Privosegtor, a potential first neuroprotective therapy for optic neuritis, at Clinical Trials at the Summit 2026 in Las Vegas. Privosegtor has shown promising Phase 2 results and received Breakthrough Therapy and PRIME designations, advancing in the PIONEER registrational trials. This drug could address significant unmet needs in optic neuritis and other neuro-ophthalmic diseases, where no approved neuroprotective treatments currently exist. The presentation highlights Oculis' progress toward late-stage development and potential transformative treatment options for patients.
BlackRock, Inc. and its funds have increased their ownership in Orion Corporation to over 5% of the company's total shares as of June 10, 2026. This change was disclosed under the Finnish Securities Market Act, indicating BlackRock's growing investme...
Core AI Holdings Inc. introduced HomeGPT, an AI-powered app for home design and renovation that lets users create and modify designs from a single photo. The launch follows a $5.4 million registered direct offering, which caused the stock to fall due...
WuXi AppTec has been conducting a significant share buyback campaign, spending about HK$1.26 billion to support its share price amid falling valuations and US regulatory pressures. The company was recently added to a US list of firms with suspected m...
SpaceX is preparing to price its IPO around $135 per share, valuing the company in the trillions and creating the first major public benchmark for the commercial space sector. This public valuation will influence how investors assess all space-relate...
Artificial Agency, an AI company specializing in generative behavior for gaming, appointed Greg Canessa as Chief Operating Officer. Canessa, a veteran with over 25 years in the gaming industry, will focus on expanding the commercial reach of the comp...
